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BACKGROUND: Li-Fraumeni syndrome (LFS) is a high-risk cancer predisposition syndrome caused by pathogenic germline variants of 
TP53. Cancer surveillance has noted a significant survival advantage in individuals with LFS; however, little is known about the feasibil-
ity, acceptance, and psychosocial effects of such a program. METHODS: Pathogenic TP53 germline variant carriers completed a 7-part 
questionnaire evaluating sociodemographics, cancer history, surveillance participation, reasons for nonadherence, worries, and distress 
adapted from the Cancer Worry Scale. Counselees' common concerns and suggestions were assessed in MAXQDA Analytics Pro 12. 
RESULTS: Forty-nine participants (46 females and 3 males), aged 40.0 ± 12.6 years, formed the study population; 43 (88%) had a per-
sonal cancer history (including multiple cancers in 10 [20%]). Forty-three individuals participated (88%) in surveillance during the study 
or formerly. Willingness to undergo surveillance was influenced by satisfaction with genetic testing and counseling (P = .019 [Fisher-Yates 
test]) but not by sociodemographics, cancer history, or distress level. Almost one-third of the participants reported logistical difficul-
ties in implementing surveillance because of the high frequency of medical visits, scheduling difficulties, and the travel distance to their 
surveillance providers. Self-reported distress and perceived emotional burden for family members and partners were moderate (median 
for self-reported distress, 3.3; median for perceived emotional burden, 3.0). For both, the interquartile range was moderate to very high 
(2.7-3.7 and 3.0-3.7, respectively). CONCLUSIONS: Individuals with LFS require efficient counseling as well as an accessible, well-organized, 
interdisciplinary, standardized surveillance program to increase adherence and psychological coping. Cancer 2020;126:4032-4041.  
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INTRODUCTION
Li-Fraumeni syndrome (LFS) is a rare autosomal 
dominant cancer predisposition syndrome caused by 
pathogenic germline variants in the TP53 gene and is 
associated with excessive lifetime cancer risks from birth 
onward. The cancer spectrum is broad and includes var-
ious cancer entities such as breast cancer, adrenocorti-
cal carcinoma, brain tumors, sarcomas, and leukemia.1-3 
Because radiation-induced secondary cancers have been 
described, surveillance methods without radiation are 
preferred. International guidelines currently recommend 
that individuals with high-risk variants of TP53 undergo 
regular surveillance visits, which should include physical 
examinations, blood tests, abdominal sonography, colo-
noscopy, annual dermatologic examinations, and further 
imaging such as annual breast and brain magnetic reso-
nance imaging (MRI) as well as annual whole-body mag-
netic resonance imaging (WB-MRI).4-8 A recent study 
has noted a significant survival advantage for individuals 
with LFS undergoing surveillance,4 and benefits from 
WB-MRI have been documented by several additional 
studies.9-12 Although a structured and standardized sur-
veillance program has not been implemented yet for 
routine care in Germany, specialized centers offer com-
prehensive surveillance according to international recom-
mendations. Often, individuals with LFS and physicians 
face time-consuming, burdensome inquiries by insurance 
companies for coverage, and this causes another burden 
for the affected in addition to the cancer risks.
Little is known about the feasibility and acceptance 
of this extensive surveillance program for individuals with 
LFS. Here we investigated cancer surveillance habits and 




The study was open to adults with a class 4 or 5 TP53 
variant (“likely pathogenic” or “pathogenic”) accord-
ing to the American College of Medical Genetics and 
Genomics guidelines.13 TP53 germline variant carri-
ers were recruited between December 2016 and May 
2018. Most participants were identified by the German 
Consortium for Hereditary Breast and Ovarian Cancer 
(GC-HBOC), which currently comprises 20 university 
hospitals and offers state-of-the-art care for women 
with hereditary breast and ovarian cancer (HBOC) 
risk variants (http://www.konso rtium -famil iaere r-brust 
krebs.de/), including TP53. These individuals’ TP53 
variants were identified via diagnostic multigene se-
quencing panels (eg, the TruRisk panel) as previously 
described.14-16 In GC-HBOC centers, genetic counseling 
is performed by multidisciplinary teams, including a 
consultation with a physician/geneticist, a gynecologist, 
and a psychologist. The study was also open to adult 
individuals with LFS who were recruited by cooperat-
ing pediatric oncologists caring for families with LFS 
(http://www.krebs -praed ispos ition.de/en/).
Study Protocol
Cooperating centers identified potential participants via 
their respective databases and reported the number to the 
initiating center in Heidelberg, Germany. Participants 
received a study-specific questionnaire with a pseu-
donymized code from their center as well as a prepaid 
envelope. After 1 month, returned documents with the 
pseudonymization codes were communicated to the coop-
erating centers, which then recontacted their nonrespond-
ers. Candidates were included if a completed questionnaire 
and a signed consent form were returned. The study pro-
tocol was approved by the ethics committee in Heidelberg 
(S-370/2016) and by each participating center.
Study Instruments
A 7-part questionnaire with 68 items captured sociode-
mographic data in addition to individual and family 
cancer histories. This analysis included adherence to 
surveillance modalities, risk awareness, personal con-
cerns, and LFS-related worries and distress (Supporting 
Table 1).
Adherence to Surveillance Modalities and 
Genetic Counseling
Adherence was assessed with 11 self-designed study-
specific items (Supporting Table 1). If the participants 
intended to participate or had already participated in 
recommended surveillance measures, they were con-
sidered adherent. Participants who actively chose to 
perform less or stop surveillance were defined as nonad-
herent. If inconsistent answers regarding nonadherent or 
adherent surveillance were detected, participants’ free-
text responses were analyzed to group those individuals 
additionally. Counselees’ retrospective experiences with 
genetic testing and counseling were evaluated with 5 self-
designed questions (Q22-Q26 in Supporting Table 1).
Distress, Worries, and Risk Awareness
Distress and worries were assessed with the Cancer 
Worry Scale (5 items; Supporting Table 1).17-21 Three 
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items on self-reported distress were included: burdened 
thoughts due to the pathogenic gene variant (Q12), 
impairment due to burdening thoughts (Q13), and 
worries about children and family members (Q16). 
Two items were included for the perceived emotional 
burden of a partner (Q14) and the family (Q15).17-23 
Average scores for distress were calculated (range, 1-5). 
Higher average scores indicated higher cancer worries 
and higher related distress. The association between 
adherence and distress was analyzed for each item in 
classes: 1) low to no distress, 2) moderate distress, and 
3) quite high to a lot of perceived distress. Furthermore, 
Q12/Q13 and Q16 were aggregated for data analysis as 
well as Q14 and Q15.
Psychological and social support were evaluated with 
3 self-designed questions (Q27-Q29). As described pre-
viously, we used 4 items for estimating the cancer/cancer 
recurrence threat and the resulting impairment in daily 
life (Q17-Q20).17,18,20,24,25
Individual Concerns and Comments
Sources of distress, individual suggestions, and com-
ments were captured in 3 open-ended questions. To 
identify and describe counselees’ common concerns 
and suggestions across the data set, we conducted a 
thematic analysis, which provided a systematic frame-
work for coding qualitative data in health psychology.26 
Specifically, we applied “sources of distress” and “nec-
essary improvements for the surveillance program” as 
2 themes, whereas entire comments from participants 
served as the units of analysis for inductive coding and 
semantic categorizing. In total, we identified 37 sub-
themes in the open-ended section. To ensure transpar-
ency, we processed and analyzed all text-field comments 
in MAXQDA Analytics Pro 12.27
Statistical Analysis
The mainly descriptive statistical analyses were performed 
with Microsoft Excel, version 15.31 (170216), and SPSS 
24 (SPSS Statistics V24; IBM Corporation, Somers, 
New York). Values are presented as means and standard 
deviations, medians, minima and maxima, interquartile 
ranges, n values, and percentages. Possible differences be-
tween groups were tested with the t test, chi-square test, 
and Fisher-Yates test. All tests were 2-sided. For correla-
tion, we used Kendall’s τ coefficient (r) and considered 
P values <.01 to be significant, whereas for all other tests, 
P values <.05 were considered statistically significant. 
P values were regarded as descriptive, and no correction 
for multiple testing was performed.
RESULTS
Study Population
A total of 80 individuals with (likely) pathogenic TP53 
germline variants from 13 centers were contacted: 41 sub-
jects returned the questionnaires, and 8 additional sub-
jects contacted us directly for participation. This resulted 
in a final study cohort of 49 participants (46 females and 
3 males). Baseline characteristics of the study population 
are given in Table 1. The personal cancer diagnoses are 
shown in Table 2. TP53 variant details as well as family 
cancer histories are outlined in Supporting Tables 2 and 3. 
A positive familial cancer history was reported for 
45 participants (92%), with a total of 88 first-degree rela-
tives affected by at least 1 cancer diagnosis (Supporting 
Table 3).
Adherence to Surveillance Modalities  
and Genetic Counseling
Most individuals with LFS had general knowledge 
about recommended TP53 germline variant–specific 
surveillance (n = 38 [78%]; Q6), whereas 9 (18%) were 
unsure, and 2 (4%) were uninformed. Surveillance mo-
dalities were followed during the study or formerly by 
43 participants (88%; Q2). A total of 37 individuals 
(77%) remained adherent to the surveillance since their 
TABLE 1. Baseline Characteristics of the Study 
Population (n = 49)
Characteristic Value Characteristic Value
Sex, No. (%) Education, No. (%)
Female 46 (94) Primary school 5 (10)
Male 3 (6) Secondary school 19 (39)
Age, median ± SD 
(range), y
40.0 ± 12.6 
(18-66)
High school 14 (29)
Children, yes, No. (%) 30 (61) College/university 11 (22)
Marital status, No. (%) Country of origin, No. (%)
Single 10 (21) Germany 40 (82)
Single parent 2 (4) Other 9 (18)
In a relationship 4 (8) Smoking, No. (%)
Married 31 (63) Yes, currently 4 (8)
Divorced 2 (4) No, never 32 (65)
Current occupation, 
No. (%)
Former smoker 13 (27)
Scholar/student 8 (16) Psychological support, 
No. (%)
Housewife 4 (8) Yes 20 (41)
Freelancer 3 (6) No 26 (53)
Employee 26 (53) Not indicated 3 (6)
Pensioner 7 (14)
Unemployed 1 (2)
Insurance status, No. 
(%)
Personal cancer, No. (%) 43 (88)
State 42 (86) Several cancer typesa 10 (20)
Private 7 (14) ≥1 family member with 
cancer, No. (%)
45 (92)
aThis includes all study participants who had at least 2 cancers.
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LFS diagnosis, whereas 2 (4%) stopped participating in 
a surveillance program, and 9 (19%) intentionally at-
tended less often than recommended; they formed the 
nonadherence group (n = 11 [23%]). One individual 
did not provide all the required information for this sec-
tion and was considered a missing value. The adherence 
and nonadherence groups did not differ significantly in 
terms of the following: country of origin, health insur-
ance or educational status, current employment, num-
ber of children, familial cancer history, psychological 
support, and logistical difficulties (Table 3). Logistical 
difficulties in implementing surveillance were stated by 
13 of the 44 participants (30%); adherent participants 
especially claimed more organizational problems (n = 
10 [77%] vs n= 3 [23%]; Table 3). Causes for declined 
surveillance in the nonadherence group were frequent 
confrontation with the condition (3 of 11) and the 
belief that further adherence would not be necessary 
after prophylactic mastectomy (2 of 11). Two female 
participants stopped surveillance after undergoing uni-
lateral therapeutic mastectomy in combination with 
simultaneous contralateral prophylactic mastectomy 
for breast cancer, with one citing the frequent confron-
tation with cancer and the other citing organizational 
problems with missing cost coverage for WB-MRI. 
Insurance companies covered the surveillance fully for 
57% (n = 28) and partially for 12% (n = 6), whereas 
31% of the participants (n = 15) could not provide any 
information on the coverage by their health insurance.
All 6 participants without a personal cancer history 
showed good adherence, whereas 31 of the 43 participants 
with a personal cancer history did (P = .313 [univariate 
Fisher-Yates test]). Adherent individuals were more likely 
to be satisfied with genetic testing (32 of 37 adherent in-
dividuals vs 6 of 11 nonadherent individuals; P =  .019 
[univariate Fisher-Yates test]; Table 3) and to recommend 
it to family members (28 of 37 vs 4 of 11; P = .049 [uni-
variate Fisher-Yates test]; Table 3).
Distress, Worries, and Risk Awareness
Many participants reported being moderately burdened 
by thoughts of LFS (n = 23 [47%]; top row in Fig. 1), 
whereas most experienced strong to very strong wor-
ries for family members (n = 28 [57%]; middle row in 
Fig. 1). This was also reflected in the aggregated data: 
average distress was moderate (median for Q12, Q13, 
and Q16, 3.3; interquartile range, 2.7-3.7; median for 
Q14 and Q15, 3.0; interquartile range, 3.0-3.7) with 
a moderate correlation (r) regarding these questions. 
Psychological support was sought significantly more 
often if thoughts burdened by LFS affected everyday 
life somewhat up to quite a lot or if everyday life was 
impaired by these thoughts (P  =  .027 and P  =  .001 
[Fisher-Yates test]). Interfamilial communication about 
genetic findings was good because most participants 
communicated their genetic findings to their whole 
family (n = 36 [74%]) or parts of their family (includ-
ing or not including their partner; n =  11 [22%]); 2 
participants (4%) shared no information.
Thirty of the 49 individuals with LFS (61%) esti-
mated their cancer risk adequately as quite high to very 
high (Fig. 2). Risk perception was not correlated with age 
(r = 0.027), educational degree (r = 0.198), employment 
status (r = 0.141), a familial cancer history (r = 0.065), 
or a personal cancer history (r = 0.126).
TP53 germline variant–related distress did not differ 
significantly between the adherence and nonadherence 
groups (Table 4).
Sources of Distress and Improvements for the 
Surveillance Program
Thirty-seven of the 49 participants (76%) provided free-
text comments. Data-driven thematic analysis of these 
comments yielded 2 main factors for distress and 3 main 
themes for improvements in the current cancer surveil-
lance. Extensive worries about their children’s health 
were described. Moreover, patients had to cope with the 
TABLE 2. Tumor Types Among Study Participants With a Personal Cancer History (Current or Former 
Cancer Diagnosis) at the Time of Study Participation
Tumor Type (n = 33)
Affected Individuals,  
No. (%) Multiple Tumor Types (n = 10)a
Affected Individuals, 
No. (%)
BC 27 (82) BC + STS or melanoma or basal cell carcinoma 3 (30)
Adrenocortical carcinoma 3 (9) BC + osteosarcoma 3 (30)
Cervical cancer 1 (3) BC + contralateral BC + melanoma 1 (10)
Melanoma 1 (3) BC + STS + leukemia 1 (10)
STS 1 (3) BC + contralateral BC + CC + osteosarcoma 1 (10)
STS + prostate cancer + stomach carcinoma 1 (10)
Abbreviations: BC, breast cancer; CC, colorectal cancer; STS, soft-tissue sarcoma.
aNine females and 1 male.
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significant burden tied to the frequent follow-up visits 
and the effort related to the difficult process of sched-
uling appointments at cancer care centers frequently 
located far from their homes. With respect to potential 
improvements in current practice in Germany, partici-
pants strongly pleaded for a standardized surveillance 
protocol and a central point of contact for the various 
diagnostic procedures. One participant expressed her 
belief in the benefit of surveillance as follows: “At the time 
of my cancer diagnosis, I was 22 years old. I would like to 
live a long life and participate in regular, comprehensive, 
and unified surveillance modalities.” In addition, partici-
pants articulated an urgent need for further information 
on their condition, including cancer prevention strategies 
and updates on new therapeutic options. Finally, partici-
pants requested that health insurance companies cover 
surveillance modalities fully and directly without the 
need to file multiple claims and objections. Specifically, 
patients demanded that health insurance companies cover 
the costs for WB-MRI.
DISCUSSION
This is the first study within Germany to evaluate 
adherence to cancer surveillance recommendations, 
surveillance-related distress, and psychological aspects 
in individuals with LFS. In a previous publication, 
Lammens et al28 investigated recommended surveil-
lance modalities in the Netherlands, related adherence, 
and its psychological impact. After studying TP53 vari-
ant carriers (n = 27) and family members at 50% risk 
for LFS (n  =  18) who had not received genetic test-
ing, they postulated that the majority of individuals 
TABLE 3. Adherence to Surveillance Modalities Among Study Participants
Adherence Group (n = 37), No. (%) Nonadherence Group (n = 11), No. (%) P
Children
Yes 23 (76.7) 7 (23.3) 1.000
No 14 (77.8) 4 (22.2)
Partnership
Married/stable partner 9 (69.2) 4 (30.8) .458
Other 28 (80) 7 (20)
Country of origin
Germany 28 (71.8) 11 (28.2) .950
Other 9 (100) 0 (0)
Education
Primary school + secondary school 18 (75) 6 (25) 1.000
High school + college 19 (79.2) 5 (20.8)
Insurance status
Statutory 33 (80.5) 8 (19.5) .327
Private 4 (57.1) 3 (42.9)
Personal cancer diagnosis
Yes 31 (73.8) 11 (26.2) .313
No 6 (100) 0 (0)
Familial cancer history
Yes 34 (77.3) 10 (22.7) .660
No 3 (75.0) 1 (25.0)
Logistical problems
Yes 10 (76.9) 3 (23.1) 1.000
No 24 (80) 6 (20)
Never performed surveillance 0 (0) 1 (100)
Psychological support
Yes 12 (63.2) 7 (36.8) .195
No 22 (84.6) 4 (15.4)
Undecided 3 (100) 0 (0)
I would reperform genetic testing
Yes 32 (84.2) 6 (15.8) .019a
No 0 (0) 2 (100)
Undecided 5 (62.5) 3 (37.5)
I would recommend genetic testing to 
family members
Yes 28 (87.5) 4 (12.5) .049a
No 1 (50) 1 (50)
Undecided 8 (57.1) 6 (42.9)
Only variables with a difference greater than 15% between the adherence and nonadherence groups were considered and are listed. One individual did not provide 
all information in this questionnaire section and was considered a missing value. The chi-square test or the Fisher-Yates test was used for all P values in this table. 
4 particpants did not answer this question: adherent group n = 3; nonadherent group n = 1).
aP < .05.
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FIGURE 1. Hereditary cancer–related distress in pathogenic TP53 germline mutation carriers. The questions refer to cancer-related 
thoughts within the week before study participation (Q12-Q16 in Supporting Table 1) in analogy to our previous work and the work of 
others (Vetter et al,17 Keller et al,19 Eismann et al,20 Schott et al,21 Codori et al,24 and Vernon et al25). Absolute numbers are indicated. 
LFS indicates Li-Fraumeni syndrome; NI, not indicated.
FIGURE 2. Self-evaluation of the personal state of health, cancer occurrence risk, and communication in the family after diagnosis 
in TP53 germline mutation carriers (Q17, Q18, and Q29 in Supporting Table 1) in accordance with our previous work and the work of 
others (Vetter et al,17 Keller et al,18 Eismann et al,20 Codori et al,24 and Vernon et al25). Absolute numbers are indicated. NI indicates 
not indicated.
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with LFS believed in the benefits of cancer surveil-
lance, which provided a feeling of security and control, 
and this increased adherence. Disbelief in the utility 
of surveillance and avoidance behavior due to fear or 
too much organizational effort were reasons for non-
adherence. Interestingly, our adherent cohort reported 
more organizational problems, and this supported their 
essential motivation regarding surveillance.
The notion that WB-MRI may reduce mean anxiety 
and distress and has no adverse psychological outcomes 
has been also confirmed by other investigators.10,29,30 It 
has rather been suggested that psychological distress could 
be reduced by WB-MRI and surveillance.10,28,30
A recent case-control study by Bancroft et al29 ana-
lyzed the effects of WB-MRI on psychological function-
ing and quality of life in adult TP53 variant carriers in 
comparison with healthy population controls over time. 
Even though TP53 variant carriers had significantly 
more cancer worries than controls, WB-MRI did not 
negatively influence their psychological well-being and 
quality of life independently of previous personal cancer 
diagnoses. Bancroft et al described the highest values for 
anxiety at the baseline, however, without the detection 
of any MRI-specific anxiety. The decreased distress over 
time after the availability of results supported the hy-
pothesis about concerns regarding MRI findings.
Interestingly, follow-up examinations due to MRI 
abnormalities revealed no significant difference in psy-
chological malfunctioning,29 although other studies 
have argued that a high false-positive rate for malignant 
lesions by WB-MRI could be associated with psychological 
distress.10,29
In contrast, a previous systematic review of psycho-
logical burden and quality of life with respect to both 
high cancer risk and intensified surveillance revealed 
increased distress among individuals with hereditary 
cancer syndromes at high risk for developing multiple 
tumors and a lower quality of life (especially females and 
individuals with a personal or familial cancer history).31 
This study by Gopie et al31 argued for screening tools to 
identify distressed individuals, and this should be con-
sidered in future studies with individuals with cancer 
predisposition syndrome to further address the impact 
of their personal experiences as well as coping methods. 
As for further coping strategies among individuals with 
LFS, family structures as well as familial collective sup-
port and responsibility were detected as having an out-
standing role that should be considered in the future.32
Notably, one-quarter of individuals with LFS did 
not follow current surveillance guidelines. A previously 
described reason for nonparticipation in surveillance 
programs among individuals with LFS is missing insur-
ance coverage.4 In Germany, an individual cost cover-
age request is normally submitted before the initiation 
of surveillance. Currently, cost coverage often requires 
time-consuming, burdensome explanations. An obli-
gation for insurance companies to cover cancer sur-
veillance for individuals with LFS does not yet exist in 
TABLE 4. Relationship Between Adherence, Nonadherence, and LFS-Related Distress and Sensitivity to Risk
Adherence Group (n = 37), No. (%) Nonadherence Group (n = 11), No. (%) P
Burdened thoughts by LFS
Not at all to hardly 5 (100) 0 (0)
Moderate 19 (82.6) 4 (17.4) .275
A lot to quite a lot 13 (65) 7 (35)
Worries about children and family members
Not at all to hardly 8 (80) 2 (20)
Moderate 5 (55.6) 4 (44.4) .176
Strong to quite strong 24 (85.7) 4 (14.3)
Perceived emotional burden of partner
Not at all to hardly 7 (100) 0 (0)
Moderate 17 (77.3) 5 (22.7) .504
A lot to quite a lot 11 (78.6) 3 (21.4)
Perceived emotional burden of family
Not at all to hardly 6 (60) 4 (40)
Moderate 13 (76.5) 4 (23.5) .371
A lot to quite a lot 16 (84.2) 3 (15.8)
Perceived personal cancer risk
Low to rather low 2 (50) 2 (50)
Normal 11 (91.7) 1 (8.3) .147
Rather high to high 22 (73.3) 8 (26.7)
Abbreviation: LFS, Li-Fraumeni syndrome.
The respective questions are shown in Supporting Table 1 (questions Q12, Q14-Q16, and Q18). Only variables with a difference greater than 15% between the 
adherence and nonadherence groups were considered and are listed. The Fisher-Yates test was used for all P values in this table. The questioned were grouped 
upon topic, If one answer of the grouped questions was missing, mean of the remaining grouped questions is shown. If more than one question of the group was 
not answered tehe value was set missing.
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Germany. In addition to coverage issues, logistical dif-
ficulties in implementing surveillance may lead to non-
adherence. The required methods challenge specialists 
in interdisciplinary centers including hemato-oncology, 
gastroenterology, gyneco-oncology, dermatology, and 
radiology departments. The frequent appointments, 
requiring self-initiation and often scheduled at tertiary 
care centers far from the patients’ homes, cause a bur-
den that could potentially be prevented through, for ex-
ample, the introduction of modern technologies such 
as cell phone applications that monitor and summarize 
surveillance appointments, updates, and recommenda-
tions. Standard interventions such as blood tests and 
coloscopies could be performed by local centers, whereas 
other measures requiring more LFS-specific expertise 
(eg, WB-MRI) could be offered by specialized cancer 
predisposition centers conducting translational research.
Surprisingly, our study did not identify logistical 
problems and insurance status as factors significantly influ-
encing adherence. Instead, satisfaction with interdisciplin-
ary counseling significantly improved adherence in our 
cohort, and this supports the necessity of a well-structured 
counseling process before and after genetic testing. The fact 
that 2 participants stopped surveillance after mastectomy 
indicates that there is still a need for more information and 
support to handle the potential LFS cancer spectrum, and 
this needs to be addressed in counseling. Bakhuizen et al33 
discussed how especially those women who do not have a 
typical LFS family history but experience an early onset of 
breast cancer need appropriate counselling strategies, and 
this needs to be examined in larger studies.
Interestingly, the observed moderate individual 
distress and cancer worry levels were lower than ex-
pected in light of the literature and the high lifetime 
cancer risk (up to 100%) for those with LFS.1,30,31,34-
38 A considerable proportion of the study participants 
(31%) underestimated their own cancer risk, and this 
was consistent with previous reports by others.29,37 This 
factor could have been caused by insufficient informa-
tion, repression of thoughts on the disease, or a lack 
of knowledge about TP53 germline variant–associ-
ated cancer risks in both patients and their physicians. 
Familial cancer experiences with death and traumatic 
grief can cause high psychological distress and inse-
curity and influence cancer risk perception.24,38-42 In 
particular, a high number of cancer diagnoses among 
first-degree relatives in families with LFS and being a 
healthy variant carrier caused greater cancer-specific 
distress among individuals with LFS.38 Our probands 
were mostly recruited on the basis of the GC-HBOC 
criteria, which also include women with early-onset 
breast cancer and without the classic LFS cancer spec-
trum or family history. Therefore, a direct comparison 
with previous studies is problematic. Nevertheless, our 
results confirm the notion that worries about family 
members and children are severe. Self-reported distress 
about relatives was identified by nearly 60% of the 
participants and was expressed in open comments de-
scribing extensive worries, particularly about children’s 
health. This is in accordance with findings by Inhestern 
et al,43 who reported that 1 of 3 cancer survivors were 
strongly concerned about the impact of their disease on 
their children. Although having children and, in partic-
ular, having younger daughters were found to be signif-
icant predictors for good adherence in individuals with 
HBOC in our previous investigations,17 the current 
study did not identify this association except for dis-
tress. Another study detected that TP53 germline vari-
ant carriers were concerned about the burden to which 
they were exposing their partner in case of early death, 
including caring for surviving children.44
Our study was limited by a self-selection bias of par-
ticipating TP53 germline variant carriers. Active study de-
cliners or nonresponders could avoid confrontation with 
their genetic disease, and this possibly correlated with 
decreased adherence to surveillance and a higher level 
of distress. In contrast, study participants could be more 
cooperative and most likely had a better coping attitude 
toward follow-up, surveillance, and distress. Furthermore, 
most participants were recruited via the GC-HBOC 
and were preselected by their HBOC family history. 
Therefore, a specific study population with a potentially 
milder LFS phenotype was addressed. This study and its 
statistical analyses are limited by the small sample size and 
differing time points for cancer, genetic testing, and sur-
veillance, although this cohort for this rare syndrome is, to 
our knowledge, the first to be addressed within Germany.
Despite these limitations, our results support the 
need for and acceptance of a well-structured, interdisci-
plinary program for adult TP53 germline variant carriers. 
Our results did not show excess distress, and adherence 
was acceptable. Carriers of a pathogenic germline vari-
ant in TP53 suffer from increased fears about themselves 
and their family members. Our results support the need 
for optimization of the current surveillance system in 
Germany for individuals with LFS to facilitate adherence. 
Counseling influences adherent behavior; therefore, a 
clearly structured plan is desirable not only for individu-
als with LFS but also for health care providers to get the 
most recent information about this rare disease. Ongoing 
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studies are aimed at developing “individual-risk-adapted” 
surveillance programs and studying the associated psy-
chosocial burden and needs as well as further translational 
aspects of LFS.
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